| __timestamp | Ligand Pharmaceuticals Incorporated | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 12122000 | 382096000000 |
| Thursday, January 1, 2015 | 13380000 | 345927000000 |
| Friday, January 1, 2016 | 21221000 | 312303000000 |
| Sunday, January 1, 2017 | 26887000 | 325441000000 |
| Monday, January 1, 2018 | 27863000 | 368298000000 |
| Tuesday, January 1, 2019 | 55908000 | 492381000000 |
| Wednesday, January 1, 2020 | 59392000 | 455833000000 |
| Friday, January 1, 2021 | 69012000 | 526087000000 |
| Saturday, January 1, 2022 | 36082000 | 633325000000 |
| Sunday, January 1, 2023 | 24537000 | 729924000000 |
| Monday, January 1, 2024 | 729924000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Takeda Pharmaceutical Company Limited and Ligand Pharmaceuticals Incorporated have demonstrated contrasting strategies in their R&D investments.
From 2014 to 2023, Takeda's R&D expenses have surged by approximately 91%, reflecting its robust focus on pioneering new treatments. In 2023 alone, Takeda allocated a staggering 730 billion yen to R&D, underscoring its strategic emphasis on long-term growth. In contrast, Ligand Pharmaceuticals, while significantly smaller, has shown a more modest increase of around 102% in R&D spending over the same period, peaking in 2021.
This divergence highlights the varied approaches these companies take in navigating the competitive landscape, with Takeda's substantial investments positioning it as a leader in pharmaceutical innovation.
R&D Insights: How AstraZeneca PLC and Takeda Pharmaceutical Company Limited Allocate Funds
Research and Development Expenses Breakdown: Pfizer Inc. vs Takeda Pharmaceutical Company Limited
Research and Development: Comparing Key Metrics for Sanofi and Takeda Pharmaceutical Company Limited
Research and Development Expenses Breakdown: Takeda Pharmaceutical Company Limited vs BioMarin Pharmaceutical Inc.
Research and Development Expenses Breakdown: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc.
Comparing Innovation Spending: Takeda Pharmaceutical Company Limited and Xenon Pharmaceuticals Inc.
Takeda Pharmaceutical Company Limited vs Amphastar Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Takeda Pharmaceutical Company Limited and Xencor, Inc.
Research and Development Expenses Breakdown: argenx SE vs Ligand Pharmaceuticals Incorporated
R&D Insights: How HUTCHMED (China) Limited and Ligand Pharmaceuticals Incorporated Allocate Funds
Analyzing R&D Budgets: Ligand Pharmaceuticals Incorporated vs Celldex Therapeutics, Inc.
R&D Insights: How Ligand Pharmaceuticals Incorporated and Travere Therapeutics, Inc. Allocate Funds